Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • nusaiba nusaiba Oct 17, 2013 2:07 PM Flag

    Hot News!MKM Partners analyst Jon LeCroy lowered his price target on Amarin Corporation (NASDAQ: AMRN) from $9 to $5 an FDA Advisory Committee voted 9 to 2 against recommending approval for the Vascepa ANCHOR indication, which he called a "major negative" for Amarin. The firm maintained a Buy rating.

    MKM Partners analyst Jon LeCroy lowered his price target on Amarin Corporation (NASDAQ: AMRN) from $9 to $5 an FDA Advisory Committee voted 9 to 2 against recommending approval for the Vascepa ANCHOR indication, which he called a "major negative" for Amarin. The firm maintained a Buy rating.

    "The panel generally felt that cardiovascular (CV) benefits to lowering moderate triglycerides have not been proven and would wait on the results of the CV outcomes trial REDUCE-IT (expected 4Q17)," LeCroy notes. "The FDA does not have to follow the panel’s recommendation but likely will and we assume the indication gets a Complet
    e

 
AMRN
2.00-0.10(-4.76%)Jun 24 4:00 PMEDT